Figures
Abstract
Selenium (Se) is an essential micronutrient that exerts its functions via selenoproteins. Little is known about the role of Se in inflammatory bowel disease (IBD). Epidemiological studies have inversely correlated nutritional Se status with IBD severity and colon cancer risk. Moreover, molecular studies have revealed that Se deficiency activates WNT signaling, a pathway essential to intestinal stem cell programs and pivotal to injury recovery processes in IBD that is also activated in inflammatory neoplastic transformation. In order to better understand the role of Se in epithelial injury and tumorigenesis resulting from inflammatory stimuli, we examined colonic phenotypes in Se-deficient or -sufficient mice in response to dextran sodium sulfate (DSS)-induced colitis, and azoxymethane (AOM) followed by cyclical administration of DSS, respectively. In response to DSS alone, Se-deficient mice demonstrated increased morbidity, weight loss, stool scores, and colonic injury with a concomitant increase in DNA damage and increases in inflammation-related cytokines. As there was an increase in DNA damage as well as expression of several EGF and TGF-β pathway genes in response to inflammatory injury, we sought to determine if tumorigenesis was altered in the setting of inflammatory carcinogenesis. Se-deficient mice subjected to AOM/DSS treatment to model colitis-associated cancer (CAC) had increased tumor number, though not size, as well as increased incidence of high grade dysplasia. This increase in tumor initiation was likely due to a general increase in colonic DNA damage, as increased 8-OHdG staining was seen in Se-deficient tumors and adjacent, non-tumor mucosa. Taken together, our results indicate that Se deficiency worsens experimental colitis and promotes tumor development and progression in inflammatory carcinogenesis.
Citation: Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, et al. (2013) Dietary Selenium Deficiency Exacerbates DSS-Induced Epithelial Injury and AOM/DSS-Induced Tumorigenesis. PLoS ONE 8(7): e67845. https://doi.org/10.1371/journal.pone.0067845
Editor: Shree Ram Singh, National Cancer Institute, United States of America
Received: April 9, 2013; Accepted: May 21, 2013; Published: July 4, 2013
Copyright: © 2013 Barrett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health grants DK080221 (CSW), R01DK82813 (RFB), P50CA095103 (MKW), R01AT004821 (KTW), R01AT004821-S1 (KTW), R01DK053620 (KTW), P01CA028842 (KTW), P01CA116087 (KTW), 1F31CA167920 (CWB), and P30 DK058404 (Vanderbilt Digestive Disease Research Center), Merit Review Grants from the Office of Medical Research, Department of Veterans Affairs 1I01BX001426 (CSW) and 1I01BX001453 (KTW), and ACS-RSG 116552 (CSW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported by an NCI T-32 Supplement T32CA009592-26. This publication was also supported in part by the NCI Cancer Center Support Grant P30CA068485 utilizing the Translational Pathology shared resource, which provided tissue processing and staining services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The essential micronutrient selenium (Se) is of fundamental importance to human health. Se, through selenoproteins, has antioxidant roles, influences immune activity, and its levels are inversely correlated with cancer risk [1] and inflammatory bowel disease (IBD) [2]–[4] In the case of IBD, red blood cell glutathione peroxidase activity [5], a Se-dependent activity and mRNA levels of Sepp1 [6], a selenoprotein, are reduced.
IBD is an autoimmune inflammatory disease of the GI tract affecting as many as 1.4 million people in the United States [7]. IBD carries numerous and serious medical complications: stricture and fistula formation, infection, severe pain, anemia, and malnutrition [8]–[11]. The pathophysiology of IBD is thought to be multifactorial in origin. Genetic, microbial, and environmental factors have all been implicated, but the fundamental etiology remains unclear. Nutritional deficiencies have been a major concern in the management of IBD for decades and numerous studies have documented decreased levels of Se in IBD compared to control patients [12]–[15]. Moreover, as Se deficiencies are often seen in IBD, downregulation of several selenoproteins have also been identified. Serum selenoprotein P (Sepp1) levels are significantly lower in patients with Crohn’s disease [6] and glutathione peroxidase 1 mRNA is significantly downregulated in mononuclear cells from patients with IBD [16]. Defects in epithelial integrity contribute to IBD pathogenesis and understanding mechanisms affecting epithelial homeostasis is a priority [17]. In this regard, Se has been directly linked to WNT signaling [18] and the intrinsic apoptosis pathway [19], suggesting that it may play a role in epithelial integrity in response to injury.
Several epidemiological studies suggest that Se status is inversely correlated with cancer incidence and mortality [20]–[23], but Se supplementation trials failed to show benefit, possibly due to the fact that the advantages of Se supplementation are dependent on several factors including baseline Se status, genetic background (e.g. the existence of polymorphisms in selenoprotein genes), type of cancer, as well as the metabolic conversion and dose of Se supplements [24]. Furthermore, several selenoproteins have been correlated with cancer risk. Mutation of the selenocysteine transfer RNA gene which results in decreased expression of some selenoproteins results in reduction in murine colon cancer risk [25]. More specifically, elevated glutathione peroxidase-2 (Gpx-2) expression has been detected in colorectal adenomas [26]–[29]. Subsequently, double knockout of Gpx-1 and Gpx-2 leads to bacterial-induced intestinal inflammation and, ultimately, ileal tumor formation [30] and Gpx-2 decreases inflammation and tumors in response to inflammatory carcinogenesis [31]. Expression levels of selenoproteins including Gpx-1, Gpx-3, and Sepp1 are significantly decreased in colorectal cancer, with lowered Sepp1 expression correlating most significantly with tumor stage [32]. As such, we have shown that Gpx-3 serves as a tumor suppressor in the AOM/DSS model of CAC [33]. Thus, both selenium and selenoproteins may play pivotal roles in tumor modulation, especially in the setting of inflammatory carcinogenesis.
There may be sub-populations of CRC patients who would benefit from Se supplementation. IBD may fall into this category as it is characterized by chronic inflammation and oxidative stress [34] and ulcerative colitis and Crohn’s colitis patients are at increased risk for developing colon cancer [35]. Experimental studies demonstrating that Se deficiency exacerbates intestinal injury and tumorigenesis are not definitive. The aim of these studies was to determine whether Se deficiency exacerbates colitis and promotes inflammation-associated carcinogenesis. Mice were rendered Se-deficient via maintenance on a tightly controlled Se-deficient diet. Se-deficient mice had exacerbated colitis after DSS injury, resulting in a pro-tumorigenic microenvironment with increased cytokines, oxidative stress, and DNA damage. Furthermore, when inflammatory carcinogenesis modeling was performed, Se-deficient mice had increased tumorigenicity and more advanced lesions compared to Se-sufficient cohorts. Thus, Se supplementation in Se-deficient IBD patients may protect from mucosal injury and malignant degeneration.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institute of Animal Care and Use Committee at Vanderbilt University (protocol number: M/10-355). Every effort was made to minimize suffering.
Murine DSS Morbidity and Inflammatory Carcinogenesis Modeling
Experimental diets were Torula yeast-based and identical except for their Se contents. The basal diet contained less than 0.01 mg Se per kg (Se-deficient) and the Se-sufficient diet was the same diet supplemented with 0.25 mg Se as sodium selenite per kg. Se-deficient and -sufficient diets were prepared and pelleted to our specifications [36] by Harlan-Teklad (Madison, WI, USA). Upon weaning, Wild-type (WT) C57BL/6 mice were maintained on the experimental diets for 12 weeks prior to initiation of DSS or AOM/DSS experiments to ensure Se deficiency.
DSS at a molecular weight of 40,000–50,000 was obtained from USB Corporation (Cleveland, OH, USA). A single lot was used for all experiments described in this publication. A 3% w/v DSS solution was made in distilled water and filtered through a 0.22 µm cellulose acetate filter. This solution was then substituted for animal drinking water and barriers were placed on the automatic watering systems within each cage.
For the DSS morbidity experiments (results shown in Figures 1, 2, 3, 4), Se-sufficient (n = 15) and Se-deficient (n = 10) mice were treated with DSS (Figure 1A) until their weight loss reached 20% of their original weights, at which time they were sacrificed. Animals were weighed daily and stools were examined for consistency and the presence of blood. Stool consistency scores ranged from 0–2, with 0 = hard, normal stools, 1 = soft and spread, 2 = diarrhea-like. Presence of blood was scored with a 0 = no blood, 2 = blood present, 4 = copious amounts of blood. Values were added for each mouse.
A. Schematic for the DSS morbidity protocol. At day 0, mice were weighed and then given a 3% DSS solution in lieu of drinking water. Each day, mice were weighed and stools were obtained for analysis of blood and stool consistency (weight and stool analyses times indicated by black diamonds). Individual mice were sacrificed if their weights fell below 80% of their original weights. B. Selenium sufficient (n = 7) and deficient (n = 7) colons were analyzed for selenium concentrations. ***P<0.0001. C. Plasma glutathione peroxidase activity is quantified. ***P<0.0001.
A. Se-sufficient (n = 15) and -deficient (n = 10) mice were subjected to the DSS morbidity protocol (see Figure 1A) and percent survival was tracked. P = 0.003, Log-rank (Mantel-Cox) test. B. Stool scores were analyzed for Se-sufficient and -deficient mice on the DSS morbidity protocol. The graph depicts the average stool score for each dietary group on each day of DSS administration. P<0.001, 2-way ANOVA. C. Percent of original weight averaged for each dietary group on each day of DSS administration. P<0.01, 2-way ANOVA. D. Colitis damage scores (described in Materials and Methods) for each dietary group analyzed at the completion of the experiment (left) and representative images of Swiss rolled colons from each group (right). Top and bottom of box 25th and 75th percentile, bar represents the median value, whiskers minimum and maximum values. **P = 0.006, Students-t test.
A. mRNA expression changes in Se-sufficient (n = 4) and -deficient (n = 4) mice on from day nine of the DSS morbidity protocol. Genes were grouped based on pathways identified by PANTHER pathway analysis software. Expression was normalized to Hprt. A. TGF-β pathway alterations include Bmp8b = bone morphogenetic protein 8b, Gdf1 = Growth differentiation factor-1, Tgfβ1 = transforming growth factor beta-1, Tgfβ2 = transforming growth factor beta-2. B. EGF pathway alterations include Egf = epidermal growth factor, Igf1 = insulin-like growth factor 1, Nrg4 = neuregulin 4. C. Developmental pathway alterations include expression changes in Lta = lymphotoxin alpha, Efnb2 = ephrin-B2, Efnb3 = ephrin-B3, Fgf22 = fibroblast growth factor 22. D. The gene altered within the group titled antioxidant activity is Tpo = thyroid peroxidase. E. Immune system process alterations are demonstrated in Cxcl13 = chemokine (C-X-C motif) ligand 13, Ifnk = interferon kappa, Ctf1 = cardiotrophin 1, Ccl27 = chemokine (C-C motif) ligand 27, Ccl20 = chemokine (C-C motif) ligand 20, IL17c = interleukin 17c, IL23a = interleukin 23a. *P<0.05, **P<0.01, ***P<0.001.
A. Selenium-sufficient (n = 3, white bars) and -deficient (n = 3, black bars) mice were given 3% DSS ad lib. and maintained in metabolic cages. Urine was collected at days 0 and 3 of DSS administration and F2-isoprostanes were measured and normalized to mg of creatinine. *P = 0.05, 1-way ANOVA. B. 8-OHdG (FITC) staining was performed in Se-sufficient (n = 12) and -deficient (n = 12) mice post-DSS morbidity protocol and quantified based on number of positive cells per high-powered field (HPF, 40x) length (left). Representative staining is shown on the right. ***P<0.0001.
For the murine inflammatory carcinogenesis protocol (results shown in Figures 5–6), Se-sufficient (n = 18) or -deficient (n = 20) C57BL/6 WT mice were injected with 12.5 mg/kg AOM (Sigma-Aldrich) intraperitoneally as described in [33], [37], [38]. After a 3-day recovery period, the animals were started on the first of 3 cycles of 3% DSS ad libitum (see schematic in Figure 5A). Each cycle was 4 days in length and was separated by a 16-day recovery period. Eight days into each recovery period, murine endoscopy was performed to monitor colitis severity and tumor burden [39]. After the last cycle, animals were sacrificed following 26 days of recovery. Mice were anesthetized with isofluorane prior to exsanguination from the inferior vena cava. Blood was treated with 15 µl of a 1 mg/ml solution of disodium EDTA to prevent coagulation and plasma was separated by centrifugation for 2 minutes at 12,000×g. The colon was removed, flushed with PBS, and opened longitudinally and gross tumor counts were conducted using a dissecting microscope at 15× magnification and size measurements obtained using digital calipers. Microscopic analysis was conducted by an experienced gastrointestinal pathologist (M.K. Washington) for dysplasia on H&E stained “Swiss rolled” colons (processed by the Vanderbilt Translational Pathology Shared Resource core). Low-grade dysplasia (LGD) refers to preinvasive pedunculated, sessile, or flat plaque-like lesions with simple glandular outlines, without loss of cellularity polarity. High-grade dysplasia (HGD) are adenomas with architectural complexity, increased cytologic atypia, and loss of tumor cell polarity [40], [41]. Sections of tumor and normal adjacent colon were collected and stored in RNAlater (Qiagen, Valencia, Santa Clarita, California, USA) and a section of the most distal colon above the anus was collected and flash frozen in liquid nitrogen for protein analysis and/or determination of Se content. The remainder of the colon was “Swiss Rolled”, formalin fixed overnight, and sectioned for histological analysis.
A. Schematic of the AOM/DSS CAC protocol. Mice are injected with AOM 4 days prior to beginning the first of three 4-day cycles of DSS. There are 16 days between each DSS cycle and mice are sacrificed 26 days after their last cycle of DSS. Black circles indicate periods at which mice are endoscopically analyzed. B. Selenium sufficient (n = 18) and deficient (n = 20) mice were subjected to the AOM/DSS protocol and tumor number was analyzed. ***P = 0.0002. C. Tumors were analyzed (by pathologist M.K. Washington) for dysplasia grade (LGD = low-grade dysplasia, HGD = high-grade dysplasia) and quantified based on percent of tumors demonstrating each grade (left, HGD ***P<0.0001, Fisher’s exact test). Representative H&E stained colons are displayed on the right.
Swiss-rolled colons of Se-sufficient and –deficient mice post-AOM/DSS protocol were analyzed for proliferation and DNA damage. A. Ki67 immunohistochemistry was conducted to identify actively proliferating cells. Intratumoral proliferation index calculated from number of Ki67-positive cells per HPF (top, Se-sufficient n = 15, Se-deficient n = 20, 40×). B. Immunofluorescence for 8-OHdG was conducted according to Materials and Methods. Staining is quantified per longitudinal crypt section in 20 crypts of each mouse (top) and representative images are shown (bottom). C. 8-OHdG staining is quantified per tumor HPF (top, Se-sufficient n = 19, Se-deficient n = 20, 40×) and representative images are shown (bottom). **P = 0.009, ***P<0.0001.
Colonic Selenium Measurements
The determination of colonic Se was carried out using a modification of the fluorometric assay of Koh and Benson [42] and Sheehan and Gao [43]. Briefly, tissue was digested in nitric and perchloric acids and Se was complexed with diaminonaphthalene. Selenium-diaminonaphthalene was extracted into cyclohexane and fluorescence was measured in a Perkin-Elmer LS 55 fluorometer.
Plasma Glutathione Peroxidase Activity Assay
Plasma collected from mice was subjected to a glutathione peroxidase (Gpx) activity assay using a modified protocol [44] based on the method of Paglia and Valentine [45]. In short, 800 µl of reaction cocktail (50mmol/L potassium phosphate, pH 7.0, 1mmol/L EDTA, 1mmol/L NaN3, 0.2mmol/L glutathione) was mixed with 10 µl plasma and 90 µl water in a clear plastic cuvette and incubated at room temperature for 5 minutes. Next, 100 µl of H2O2 substrate (0.25mmol/L H2O2 in H2O) was added to the reaction mixture to initiate the reaction. Gpx activity was assessed by measuring the rate of change of A340 during the linear phase of the reaction. The rate of change was then converted to the number of µmoles of NADPH oxidized/minute using the extinction coefficient of 6.2×103 L mol−1 cm−1 for NADPH at 340 nm. Blank reactions with distilled water were subtracted from each assay.
F2-Isoprostane Analysis
DSS-treated mice (WT C57BL/6 fed Se-sufficient diets n = 3, WT C57BL/6 fed Se-deficient diets n = 3, 3% DSS ad libitum for 3 days) were housed in metabolic cages and urine was collected for 12 hours on days 0 and 3 of DSS administration. Urinary F2-isoprostanes were measured by stable isotope dilution gas chromatography mass spectrometry using [2H4]15-F2t-isoprostane as internal standard as previously described [46]. Values were normalized to mg creatinine in urine.
Histological Injury Analysis
A colitis damage score was generated from digital images of H&E stained sections, by first measuring the distance around the intact muscularis using AVP Universal Desktop Ruler software (as performed by [47]). The areas of ulceration were then measured and given scores of 1, 2, 3, or 4, where a score of 1 represents injury involving the lower 1/3 of the crypt, 2 equaling injury to the lower 2/3rds of the crypt, 3 equaling total crypt loss however the epithelial lining remains intact and 4 equaling total crypt and complete epithelial loss. The ulceration score was then multiplied by the length of the involved colon, summed, and divided by the total colon length to give a measure of ulceration severity/colon length. Measurements were performed in a blinded fashion in all colons from mice subjected to the DSS morbidity protocol.
Cytokine Array Analysis
RNA from Se-sufficient or -deficient DSS morbidity colons (collected on day nine of DSS treatment) was isolated using the RNeasy Mini Kit (Qiagen, Valencia, Santa Clarita, California, USA). cDNA was synthesized using the iScript cDNA synthesis kit (Bio-rad, Hercules, California, USA) from 1 µg of total RNA. 1 µl of the 20 µl cDNA produced through the iScript reaction was used as a template in each subsequent PCR reaction. SYBR green qRT-PCR was performed using mouse cytokine array libraries I (Cat #: MCA-I) and II (Cat #: MCA-II) purchased from RealTimePrimers.com (Elkins Park, Pennsylvania, USA) according to manufacturer’s instructions. Individual cytokines were analyzed using the delta-delta Ct method and normalized to Hypoxanthine-Guanine Phosphoribosyltransferase (Hprt). Those showing significant differences were plotted using Graphpad Prism. In order to develop the heat map, data was incorporated into the free web-based PCR array analysis software provided by SABiosciences (Qiagen).
Immunohistochemistry and Immunofluorescence Staining
Five-micrometer sections were cut, dewaxed, and hydrated. Antigen retrieval was conducted using Antigen Unmasking Reagent (Vector Laboratories, Inc., Burlingame, California, USA) according to manufacturer’s instructions. After blocking, primary antibody was added [α-Ki67 (NeoMarkers RB-1510-P, Fremont, California, USA), 1∶1,000; α-8-hydroxy-2′deoxyguanosine (8-OHdG, Abcam ab26842, Cambridge, Massachusetts, USA) 1∶50] and incubated overnight at 4°C. Isotype-matched antibodies were included as negative controls. Sections were then incubated for one hour at room temperature in secondary antibody (Ki67: Goat α-Rabbit-cy3, Invitrogen A10520; 8-OHdG: α-mouse-FITC, Sigma F-0257). Identification of apoptotic cells was conducted using the ApopTag Plus Peroxidase In Situ Apoptosis Kit (Chemicon, Temecula, California, USA) according to the manufacturer’s protocol. Control slides were obtained by omitting the terminal transferase (TnT) enzyme. For immunofluorescence staining of proliferation and DNA damage, slides were counterstained and mounted with ProLong Gold antifade including 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen, Grand Island, New York, USA). DNA damage indices were generated by counting the number of positive cells per colon length within each high-powered field, with 5 high-powered fields counted per colon, starting at the most distal colon. Apoptosis, and proliferation indices were generated by counting either the number of positive cells per high-powered field (HPF; 40x objective) within each tumor or the number of positive cells per longitudinal crypt section in 20 crypts per mouse by a blinded observer. The average score was then calculated for each Swiss-rolled colon.
Statistical Methods
Differences between Se-deficient and -sufficient mice were determined utilizing Graphpad Prism and analysis with the Student’s t-test. The survival curve was analyzed using the Log-rank (Mantel-Cox) test. Differences in stool scores and percentage weight loss were determined using two-way ANOVA for repeated measurements over time. Urine F2-isoprostane analysis of all four groups was analyzed using one-way ANOVA with a Newman-Keuls post-test to determine variances between columns. Finally, statistical analysis of high-grade dysplasia was performed using the Fisher’s Exact test.
Results
Dietary Selenium Maintains Epithelial Integrity
Se, through selenoproteins, has antioxidant roles, influences immune activity, and has been inversely correlated with IBD [4], [48] and cancer risk [1]. Because oxidative stress compromises mucosal integrity [49], and Se deficiency has been shown to increase oxidative stress [50], we determined whether dietary Se deficiency influences the severity of colitis following treatment with 3% DSS ad lib (Figure 1A). Animals were fed either Se-sufficient or -deficient diets for 12 weeks, an extended period of time sufficient to ensure Se deficiency which we confirmed via measurement of colonic mucosal Se levels at the end of the DSS experiment (333.1±16.5 vs 60.6±4.1 ng/g, P<0.0001, Figure 1B) and plasma glutathione peroxidase (Gpx) activity (215.4±31.6 vs 18.9±27.8 nmol NADPH/ml.min, P<0.0001, Figure 1C). In this experiment, mice were maintained on 3% DSS until their weight reached 80% of their original weights (survival endpoint). Se deficient mice median survival was 9 days in comparison to Se sufficient whose median survival was 12 days (P = 0.003, Figure 2A). Additionally, Se deficient mice had worsened diarrhea and increased blood in stools (stool scores at day 9∶2.7±0.7 vs 5.7±0.3, P = 0.02, Figure 2B), had accelerated weight loss (84.3±1.2 vs 77.4±1.2% of starting body weight at day 9, P = 0.01, Figure 2C), and had more severe colitis/epithelial injury (2.1±0.2 vs 2.9±0.1, P = 0.006, Figure 2D). These results indicate that Se is protective against DSS-induced colonic injury.
Pro-tumorigenic Microenvironment is Promoted by Selenium Deficiency
Inflammation, a component of the epithelial and tumor microenvironment, is a contributing factor that predisposes to malignancy and, as we had observed increased injury in response to DSS administration in Se-deficient mice, we wanted to determine whether chemokine and cytokine signaling was aberrantly regulated in Se-deficient mice in response to injury. Therefore, we analyzed Se-sufficient and -deficient colons for cytokine mRNA expression using a mouse cytokine array. Because the RNA isolated for analysis was isolated from whole colon, the source of these cytokines and chemokines would include epithelial and stromal components. This analysis yielded alterations in several chemokines and cytokines that are displayed as a heat map for all genes tested (Figure S1A and B). Significantly altered cytokines were grouped according to function using PANTHER Pathway Analysis software [51]. Transforming growth factor beta (TGF-β) signaling was altered with increased Tgf-β1 and -β2 transcripts and decreased growth differentiation factor-1 (Gdf1) and bone morphogenetic protein 8b (Bmp8b) (Figure 3A). Additionally, the EGF pathway was altered (Figure 3B), as were components of developmental programs (Figure 3C). Levels of thyroid peroxidase (Tpo), PANTHER classified as an antioxidant, was increased (0.01±0.003 vs 9.1±6.3 fold change, P = 0.04, Figure 3D), consistent with a decrease in Se leading to aberrant regulation of thyroid hormone production [52]. Supporting immune system process activation there was increased chemokine (C-X-C motif) ligand 13 (Cxcl13), interferon kappa (Ifnk), cardiotrophin 1 (Ctf1), chemokine (C-C motif) ligand 27 (Ccl27), chemokine (C-C motif) ligand 20 (Ccl20), interleukin 17c (Il-17c), and interleukin 23a (Il-23a) messenger RNA in Se-deficient states (Figure 3E). Collectively, multiple factors capable of promoting tumor development were upregulated after DSS treatment in a Se-deficient state.
Lipid Peroxidation, a Marker of Oxidative Stress, is Increased in the Urine of Selenium-deficient mice after DSS Induced Colitis
DSS administration in the drinking water causes colonic epithelial injury and a robust innate inflammatory response producing an environment enriched in reactive oxygen and nitrogen species [53]. Oxidative injury is quantifiable by measuring F2-isoprostanes (F2-IsoPs), one of the most reliable measures of in vivo lipid peroxidation, a marker of oxidative stress [46], [54]. We measured F2-IsoPs using stable isotope dilution gas chromatography mass spectrometry methodology. F2-IsoP levels were not different at baseline between Se-sufficient and -deficient mice (0 time point, Figure 4A). However, increased urine F2-IsoPs were observed in mice fed a Se-deficient diet when compared to mice on a Se-sufficient diet, after 3 days of 3% DSS (6.0±0.3 vs 9.1±1.0 ng/mg creatinine, P = 0.05, Figure 4A), indicating that Se protects from lipid peroxidation in this model. Therefore, F2-IsoPs effectively quantitate oxidative stress levels in the DSS model and Se-deficiency increases whole animal oxidative stress after DSS-induced injury.
DNA Damage is Increased in Selenium-deficient mice in Response to DSS
As inflammatory injury and lipid peroxidation were upregulated in Se-deficient mice, and because Se has been linked with DNA damage repair [55], [56], we next determined whether DNA damage was increased in these mice. Colonic epithelial 8-OHdG staining, which identifies oxidative damage to DNA, was significantly increased in Se-deficient mice after DSS injury (13.2±1.3 vs 28.8±1.6 8-OHdG+ cells/HPF length, P<0.0001, Figure 4B). Thus, Se-deficiency exacerbated colitis and was associated with increased pro-inflammatory and pro-tumorigenic cytokines and increased DNA damage. These changes collectively produce a microenvironment primed for tumorigenesis.
Dietary Selenium Protects from Inflammatory Carcinogenesis
Because Se deficiency promoted an activated pro-tumorigenic microenvironment and DNA damage after DSS treatment, we next determined if Se status modified inflammatory carcinogenesis. AOM is a procarcinogen that is metabolically activated to a potent alkylating agent forming O6-methyl-guanine [57]. Its oncogenic potential is markedly augmented in the setting of chronic inflammation, such as that induced by repeated cycles of DSS treatment [58], [59].
To determine if dietary Se modifies CAC, we modeled inflammatory carcinogenesis in Se-deficient or –sufficient C57BL/6 mice using AOM/DSS (Figure 5A). There were no significant changes in weight loss or DSS consumption during the course of this experiment (Figure S2D and E). At necropsy, Se-deficient mice demonstrated increased tumor multiplicity (3.4±0.4 vs 7.6±0.9 tumors/mouse, P = 0.0002, Figure 5B) as well as a higher degree of dysplasia (P<0.0001, Figure 5C) compared to Se-sufficient mice. Consistent with the morbidity studies (Figure 2), there was an increase in morbidity in Se-deficient mice in response to the AOM/DSS protocol (Figure S2A), though this difference was not statistically significant. We did not detect alterations in colon weight or length, however, suggesting that Se-deficient mice did not sustain chronic inflammatory changes in response to the AOM/DSS protocol (Figure S2B and C), at least when evaluated after the 26-day recovery period. Taken together, these data suggest that Se serves as a tumor suppressor that exerts its influence at the levels of tumor initiation and progression.
Selenium Deficiency Results in Increased Intratumoral Proliferation and a General Increase in DNA Damage
Several selenoproteins have been identified as direct WNT targets [60] and Se deficiency activates WNT signaling [18], implicating Se deficiency in a proliferation pathway that is aberrantly regulated in colorectal cancer. Furthermore, mitochondrial selenoproteins have been implicated in the regulation of mitochondrial-dependent cell death [19]. As we noted an increase in tumor number in Se-deficient mice, we determined whether cellular proliferation or apoptosis indices were altered. Proliferation, as measured by Ki67 staining, was increased in the tumors of Se-deficient mice (26.0±1.9 vs 39.5±2.9 Ki67+ cells/tumor HPF, P = 0.0008, Figure 6A), but not within colonic crypts (Figure S3A). Apoptosis was quantified by TUNEL staining and no difference was seen between the two groups (Figure S3B and C). Interestingly, an increase in intratumoral proliferation is generally associated with an increase in tumor size and not number. For this reason, and due to the fact that DSS results in DNA damage [33], [61] which can lead to changes in the initiation frequency, we stained crypts and tumors of Se-sufficient and -deficient mice with 8-OHdG. Consistent with what was observed in the DSS morbidity study, Se deficiency led to a significant increase in DNA damage within crypts (0.83±0.04 vs 1.1±0.08 8-OHdG+/crypt, P = 0.009, Figure 6B), as well as tumors (23.7±1.5 vs 46.8±3.7 8-OHdG+/tumor HPF, P<0.0001, Figure 6C). Indicating augmented DNA damage, potentially contributing to the increased tumorigenesis observed in Se-deficient mice.
Discussion
The essential trace element Se may be useful for the prevention and/or abrogation of several diseases related to oxidative stress including neurodegenerative, cardiovascular diseases [62]. In these diseases, Se deficiency is uncommon and thus therapeutic approaches targeting Se would require supranutritional amounts of Se for treatment. This point is important because harmful side-effects of supranutritional Se have been identified including increased risk for diabetes [63]. In contrast, IBD is a disease characterized by chronic inflammation, high oxidative stress and Se deficiency making it a potential target for Se supplementation, with the goal being to restore Se nutritional status to the normal range. In support of this concept, our results demonstrate that, in fact, Se sufficiency protects against DSS-induced injury when compared to Se deficiency as morbidity, weight loss, and mucosal injury in response to DSS were all significantly increased in mice fed a Se-deficient diet. Moreover, Se may protect against mucosal injury by decreasing expression of pro-inflammatory cytokines; as such we detected increased mRNA expression of the B cell chemoattractant chemokine (C-X-C motif) ligand 13 (Cxcl13), the T cell inflammation associated Chemokine (C-C motif) ligand 27 (Ccl27), the lymphocyte chemoattractant Chemokine (C-C motif) ligand 20 (Ccl20), as well as interleukin (Il)-17c which can promote Th17 cell responses [64]. Of particular interest is the upregulation of Il-23a, as Il-23 has been shown to be a pro-inflammatory factor and target protein for inhibitory therapy in Crohn’s disease, since it has major effects on Th17 cell differentiation [65]. These data suggest that restoration of normal Se levels may be a therapeutic option in IBD.
DSS-induced colonic injury, like ulcerative colitis, results in increased oxidative stress, which is at least partly attributable to immune cell infiltration and the release of inflammatory mediators [66], [67]. One method to quantify oxidative injury is to assess lipid peroxidation via measurement of F2-isoprostanes (F2-IsoPs), non-enzymatic derivatives of arachidonic acid [46]. It is important to note that, although lipid peroxidation is an indirect measure of oxidative stress, the Biomarkers of Oxidative Stress Study (BOSS) identified F2-IsoPs as the most reliable index of in vivo oxidative stress when compared against other known biomarkers [54]. Other labs have demonstrated increased F2-IsoPs in response to DSS using the Cayman assay [68], [69]. We utilized stable isotope dilution gas chromatography mass spectrometry analysis of F2-IsoPs to demonstrate that Se deficiency further augments the effects of DSS, indicating that DSS-induced lipid peroxidation, an indicator of oxidative injury, is increased in response to Se deficiency upon DSS administration and implicating Se in protection from lipid peroxidation in the DSS model.
Chronic inflammation and cyclic epithelial injury characteristic of IBD results in increased cancer risk, although the magnitude of this risk is unclear [35]. In our studies we found that Se deficiency leads to increased colonic injury and inflammation. Additionally, several TGF-β signaling components were aberrantly expressed in Se-deficient mice after DSS treatment. Transcripts for bone morphogenetic protein 8b (Bmp8b), which important for primordial germ cell determination [70], and a second TGF-β family member, growth differentiation factor 1 (Gdf1), were downregulated in DSS-treated Se-deficient mice. Gdf1 is correspondingly underexpressed in salivary gland adenoid cystic carcinoma [71] suggesting a potential role as a tumor suppressor. Furthermore, Tgf-β1 gene expression is upregulated in Se-deficient mice and has been implicated in the pathogenesis of colorectal neoplasia and several polymorphisms have been identified in colorectal adenoma which lead to Tgf-β1 overexpression [72], [73]. Tgf-β2, also identified as overexpressed in Se-deficient mice, has been linked with tumor promotion as it is upregulated in colorectal, breast, pancreatic, and brain cancer [74].
Transcripts of the EGF pathway are also upregulated in Se-deficient mice with pathway members including epidermal growth factor (Egf), insulin-like growth factor 1 (Igf1) and neuregulin 4 (Nrg4) all demonstrating increased expression in Se-deficient compared to -sufficient mice subjected to the DSS morbidity protocol. EGF is upregulated nearly 3-fold in colorectal carcinoma [75] and the EGF signaling pathway is intimately linked to promotion of solid tumor growth [76]. These data coupled with the fact that we also see increased expression of the ephrins Efnb2 and Efnb3, which are known to contribute to tumor promotion as well as progression [77], suggest that the signaling cascades and inflammation resulting from Se deficiency after DSS injury may result in increased cancer risk.
Beyond activation of oncogenic signaling pathways, Se deficiency may promote tumorigenesis via affecting genomic integrity [55]. Supplementation with moderate levels of Se compounds both in vivo and in vitro is thought to protect against the formation of DNA adducts and maintain chromosomal stability and telomere length and function [56]. In support of this we found that Se deficiency did, in fact, increase DNA adduct formation, a marker of DNA damage, after DSS-induced colonic stress, suggesting another mechanism by which Se might inhibit tumorigenesis in CAC.
Two prior studies report on the effects of reduced dietary Se in inflammatory colon tumorigenesis. Both have demonstrated a subtle, non-significant, increase in tumorigenesis with decreased dietary selenium [31], [78]. There are several potential explanations for why we observed a significant increase in tumor burden in our studies; 1) Differences in model selection, 2) strain of mice studied, and 3) degree and magnitude of Se deficiency. Our mice were fed Se-deficient diets (less than 0.01 mg Se/kg) for 12 weeks prior to the initiation of our protocols. This extensive time-frame was selected because our group has previously determined that this will ensure Se deficiency [79]. In our current studies we confirmed Se deficiency by measuring plasma Gpx activity and colonic Se levels. In contrast, the prior studies used low Se diets (0.02 and 0.086 mg Se/kg, respectively) for shorter time periods before protocol initiation. Our AOM/DSS protocol employs a single injection of AOM followed by cyclical administration of 3% DSS. Using this protocol, we achieved a tumor penetrance of 100% revealing a significant role of Se deficiency in inflammatory carcinogenesis. Furthermore, our data suggest that Se may also protect from tumor progression as more advanced lesions occurred in the setting of Se deficiency.
There is considerable epidemiological evidence indicating that Se levels and cancer are inversely correlated [20], [22]–[24]. Dietary intervention studies targeting Se have been inconsistent, however. Our findings suggest that Se supplementation, as a therapeutic intervention, should be targeted to patient populations, or individual patients, with demonstrable selenium deficiency. Importantly, our data indicate that patients with IBD, a disease in which Se deficiency occurs, might benefit from Se supplementation to prevent CAC. Beyond IBD and CAC, there needs to be a concerted effort towards fully understanding the molecular basis for how Se protects from tumorigenesis, in what cancers Se is important, at what dietary levels Se is most beneficial, and in which patient populations selenium supplementation might have a beneficial impact.
Supporting Information
Figure S1.
Cytokines are aberrantly regulated in seleniumdeficient mice subjected to DSS. A. Heat map of mouse cytokine library I and B. mouse cytokine library II gene expression in Se-deficient (n = 4) versus -sufficient (control, n = 4) colons post-DSS morbidity (left) and a chart of represented cytokines (right). Green = underexpression, Red = overexpression where intensity of color indicates increasing distance from 0; Grey = qRT-PCR yields were undetectable.
https://doi.org/10.1371/journal.pone.0067845.s001
(TIF)
Figure S2.
Selenium levels do not significantly impact survival, colon weight, colon length, or mouse weight in response to AOM/DSS. A. Survival curve of Se-deficient and -sufficient mice in response to the AOM/DSS protocol. B. Colon weight (g) and C. colon length (mm) post-AOM/DSS protocol. D. Mouse weight (g) throughout the AOM/DSS protocol measured on days 0, 1, 3, 4, and 7 of DSS administration during each DSS cycle. E. DSS consumption/mouse during the four days of DSS administration.
https://doi.org/10.1371/journal.pone.0067845.s002
(TIF)
Figure S3.
Crypt proliferation and crypt and tumor apoptosis are unaltered in dietary models in response to AOM/DSS. A. Quantification of Ki67 staining within crypts in non-tumor bearing areas of Se-sufficient and -deficient mice. 20 crypts were counted for each mouse. B. Crypt and C. intratumoral TUNEL counts in Se-sufficient and -deficient mice.
https://doi.org/10.1371/journal.pone.0067845.s003
(TIF)
Acknowledgments
The authors thank Teri Stevenson and Michelle Chatterton for help with animal husbandry, members of the Williams and Burk laboratories for thoughtful discussions about this research project.
Author Contributions
Conceived and designed the experiments: CWB KS SSD RFB CSW. Performed the experiments: CWB KS AKM MKL EM AMB WN SVP BP VKR MKW. Analyzed the data: CWB KS AKM MKL KTW CSW. Contributed reagents/materials/analysis tools: KS AKM BMF KTW SSD KEH RFB CSW. Wrote the paper: CWB KTW SSD KEH RFB CSW. None.
References
- 1. Rayman MP (2000) The importance of selenium to human health. Lancet 356: 233–241
- 2. Kuroki F, Matsumoto T, Iida M (2003) Selenium is depleted in Crohn’s disease on enteral nutrition. Dig Dis 21: 266–270
- 3. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ (1997) Circulating antioxidant concentrations in children with inflammatory bowel disease. Am J Clin Nutr 65: 1482–1488.
- 4. Rannem T, Ladefoged K, Hylander E, Hegnhøj J, Jarnum S (1992) Selenium status in patients with Crohn’s disease. Am J Clin Nutr 56: 933–937.
- 5. Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B (2000) Antioxidant and immune status in active Crohn’s disease. A possible relationship. Clin Nutr 19: 43–48
- 6. Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, et al. (2005) Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition (Burbank, Los Angeles County, Calif) 21: 574–579
- 7. Loftus EV (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126: 1504–1517.
- 8. Kirsner JB (1979) The local and systemic complications of inflammatory bowel disease. JAMA 242: 1177–1183.
- 9. Kirsner JB (1991) Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. Dis Mon 37: 669–746.
- 10. Kirsner JB (1991) Inflammatory bowel disease. Part I: Nature and pathogenesis. Dis Mon 37: 605–666.
- 11. Vatn MH (2009) Natural history and complications of IBD. Curr Gastroenterol Rep 11: 481–487.
- 12. Ringstad J, Kildebo S, Thomassen Y (1993) Serum selenium, copper, and zinc concentrations in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 28: 605–608
- 13.
Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR (1999) Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 28: 423–43–ix.
- 14. Sturniolo GC, Mestriner C, Lecis PE, D’Odorico A, Venturi C, et al. (1998) Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand J Gastroenterol 33: 644–649.
- 15. Ojuawo A, Keith L (2002) The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 48: 116–119.
- 16. Mannick EE, Bonomolo JC, Horswell R, Lentz JJ, Serrano M-S, et al. (2004) Gene expression in mononuclear cells from patients with inflammatory bowel disease. Clin Immunol 112: 247–257
- 17.
Denson LA, Long MD, McGovern DPB, Kugathasan S, Wu GD, et al.. (2013) Challenges in IBD Research: Update on Progress and Prioritization of the CCFA’s Research Agenda. Inflamm Bowel Dis: –. https://doi.org/10.1097/MIB.0b013e31828134b3
- 18. Kipp A, Banning A, van Schothorst EM, MÃ Plan C, Schomburg L, et al. (2009) Four selenoproteins, protein biosynthesis, and Wnt signalling are particularly sensitive to limited selenium intake in mouse colon. Mol Nutr Food Res 53: 1561–1572
- 19. Yin F, Sancheti H, Cadenas E (2012) Mitochondrial thiols in the regulation of cell death pathways. Antioxid Redox Signal 17: 1714–1727
- 20. Schrauzer GN (1977) Trace elements, nutrition and cancer: perspectives of prevention. Adv Exp Med Biol 91: 323–344.
- 21. Combs GF, Gray WP (1998) Chemopreventive agents: selenium. Pharmacol Ther 79: 179–192.
- 22. Jaworska K, Gupta S, Durda K, Muszyńska M, Sukiennicki G, et al. (2013) A low selenium level is associated with lung and laryngeal cancers. PLoS ONE 8: e59051
- 23. Clark LC, Cantor KP, Allaway WH (1991) Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46: 37–42
- 24.
Steinbrenner H, Speckmann B, Sies H (2013) Toward Understanding Success and Failures in the Use of Selenium for Cancer Prevention. Antioxid Redox Signal. https://doi.org/10.1089/ars.2013.5246
- 25. Irons RR, Carlson BAB, Hatfield DLD, Davis CDC (2006) Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. J Nutr 136: 1311–1317.
- 26. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mörk H, et al. (2004) Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer 48: 6–14
- 27. Florian S, Wingler K, Schmehl K, Jacobasch G, Kreuzer OJ, et al. (2001) Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue. Free Radic Res 35: 655–663.
- 28. Mörk H, al-Taie OH, Bähr K, Zierer A, Beck C, et al. (2000) Inverse mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in colorectal adenomas compared with adjacent normal mucosa. Nutr Cancer 37: 108–116.
- 29. Lin Y-M, Furukawa Y, Tsunoda T, Yue C-T, Yang K-C, et al. (2002) Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120–4128
- 30. Chu F-F, Esworthy RS, Chu PG, Longmate JA, Huycke MM, et al. (2004) Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 64: 962–968.
- 31. Krehl S, Loewinger M, Florian S, Kipp AP, Banning A, et al. (2012) Glutathione peroxidase-2 and selenium decreased inflammation and tumors in a mouse model of inflammation-associated carcinogenesis whereas sulforaphane effects differed with selenium supply. Carcinogenesis 33: 620–628
- 32. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, et al. (2008) Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 259: 218–230
- 33. Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, et al. (2013) Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Research 73: 1245–1255
- 34. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, et al. (2007) Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci 52: 1636–1641
- 35. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228–1233.
- 36. Hill KE, Zhou J, McMahan WJ, Motley AK, Burk RF (2004) Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene. J Nutr 134: 157–161.
- 37. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296
- 38. Barrett CW, Fingleton B, Williams A, Ning W, Fischer MA, et al. (2011) MTGR1 Is Required for Tumorigenesis in the Murine AOM/DSS Colitis-Associated Carcinoma Model. Cancer Res 71: 1302–1312
- 39. Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, et al. (2005) In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut 54: 950–954
- 40.
Washington MK, Powell AE, Sullivan R, Sundberg J (2013) Pathology of Rodent Models of Intestinal Cancer: Progress Report and Recommendations. Gastroenterology.
- 41. Boivin GPG, Washington KK, Yang KK, Ward JMJ, Pretlow TPT, et al. (2003) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762–777
- 42. Koh TS, Benson TH (1983) Critical re-appraisal of fluorometric method for determination of selenium in biological materials. J Assoc Off Anal Chem 66: 918–926.
- 43. Sheehan TM, Gao M (1990) Simplified fluorometric assay of total selenium in plasma and urine. Clin Chem 36: 2124–2126.
- 44. Lawrence RA, Burk RF (1976) Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71: 952–958.
- 45. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158–169.
- 46. Milne GL, Sanchez SC, Musiek ES, Morrow JD (2007) Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2: 221–226
- 47. Koller FL, Dozier EA, Nam KT, Swee M, Birkland TP, et al. (2012) Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab Invest 92: 1749–1759
- 48. Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, et al. (2012) Selenium, Selenoprotein Genes and Crohn’s Disease in a Case-Control Population from Auckland, New Zealand. Nutrients 2012, Vol 4, Pages 1247–1259 4: 1247–1259
- 49. Circu ML, Aw TY (2012) Intestinal redox biology and oxidative stress. Semin Cell Dev Biol 23: 729–737
- 50. Burk RF, Hill KE, Nakayama A, Mostert V, Levander XA, et al. (2008) Selenium deficiency activates mouse liver Nrf2-ARE but vitamin E deficiency does not. Free Radic Biol Med 44: 1617–1623
- 51. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13: 2129–2141
- 52. Beckett GJ, Arthur JR (2005) Selenium and endocrine systems. J Endocrinol 184: 455–465
- 53. Seril DN, Liao J, Yang G-Y, Yang CS (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24: 353–362.
- 54. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, et al. (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38: 698–710
- 55. Bera S, De Rosa V, Rachidi W, Diamond AM (2013) Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? Mutagenesis 28: 127–134
- 56. Ferguson LR, Karunasinghe N, Zhu S, Wang AH (2012) Selenium and its’ role in the maintenance of genomic stability. Mutat Res 733: 100–110
- 57. Pegg AE (1984) Methylation of the O6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest 2: 223–231.
- 58. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694–702.
- 59. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87–92.
- 60. Kipp AP, Müller MF, Göken EM, Deubel S, Brigelius-Flohé R (2012) The selenoproteins GPx2, TrxR2 and TrxR3 are regulated by Wnt signalling in the intestinal epithelium. Biochim Biophys Acta 1820: 1588–1596
- 61. Hong MY, Turner ND, Carroll RJ, Chapkin RS, Lupton JR (2005) Differential response to DNA damage may explain different cancer susceptibility between small and large intestine. Exp Biol Med (Maywood) 230: 464–471.
- 62. Huang Z, Rose AH, Hoffmann PR (2012) The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16: 705–743
- 63. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, et al. (2007) Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147: 217–223.
- 64. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, et al. (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 35: 611–621
- 65. Neurath MF (2007) IL-23: a master regulator in Crohn disease. Nat Med 13: 26–28
- 66. Damiani CR, Benetton CAF, Stoffel C, Bardini KC, Cardoso VH, et al. (2007) Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 22: 1846–1851
- 67. Trivedi PP, Jena GB (2013) Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact 201: 19–30
- 68. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, et al. (2000) NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 279: G1298–G1306.
- 69. Carrier J, Aghdassi E, Cullen J, Allard JP (2002) Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 132: 3146–3150.
- 70. Ying Y, Liu XM, Marble A, Lawson KA, Zhao GQ (2000) Requirement of Bmp8b for the generation of primordial germ cells in the mouse. Mol Endocrinol 14: 1053–1063.
- 71. Frierson HF, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, et al. (2002) Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161: 1315–1323
- 72. Langenskiöld M, Holmdahl L, Falk P, Angenete E, Ivarsson M-L (2008) Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 97: 409–415
- 73. Saltzman BS, Yamamoto JF, Decker R, Yokochi L, Theriault AG, et al. (2008) Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Research 68: 1236–1244
- 74. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1–6.
- 75.
Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, et al.. (2010) Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE 5: –. https://doi.org/10.1371/journal.pone.0013091
- 76. Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4: 277–296.
- 77. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nature Reviews Cancer 10: 165–180
- 78. Cho M, Kim J-H, Hue J-J, Kang BS, Park H, et al. (2010) Effect of Dietary Selenium on the Colon Carcinogenesis in Male ICR Mice. Journal of Food Hygiene Safety 25: 269–277.
- 79. Hill KE, Zhou J, McMahan WJ, Motley AK, Atkins JF, et al. (2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 278: 13640–13646